title: The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation.
abstract: Respiratory syncytial virus (RSV) is an important cause of acute respiratory disease in infants, immunocompromised subjects and the elderly. However, it is unclear why most primary RSV infections are associated with relatively mild symptoms, whereas some result in severe lower respiratory tract infections and bronchiolitis. Since RSV hospitalization has been associated with respiratory bacterial co-infections, we have tested if bacterial Toll-like receptor (TLR) agonists influence RSV-A2-GFP infection in human primary cells or cell lines. The synthetic bacterial lipopeptide Pam3-Cys-Ser-Lys4 (Pam3CSK4), the prototype ligand for the heterodimeric TLR1/TLR2 complex, enhanced RSV infection in primary epithelial, myeloid and lymphoid cells. Surprisingly, enhancement was optimal when lipopeptides and virus were added simultaneously, whereas addition of Pam3CSK4 immediately after infection had no effect. We have identified two structurally related lipopeptides without TLR-signaling capacity that also modulate RSV infection, whereas Pam3CSK4-reminiscent TLR1/2 agonists did not, and conclude that modulation of infection is independent of TLR activation. A similar TLR-independent enhancement of infection could also be demonstrated for wild-type RSV strains, and for HIV-1, measles virus and human metapneumovirus. We show that the effect of Pam3CSK4 is primarily mediated by enhanced binding of RSV to its target cells. The N-palmitoylated cysteine and the cationic lysines were identified as pivotal for enhanced virus binding. Surprisingly, we observed inhibition of RSV infection in immortalized epithelial cell lines, which was shown to be related to interactions between Pam3CSK4 and negatively charged glycosaminoglycans on these cells, which are known targets for binding of laboratory-adapted but not wild-type RSV. These data suggest a potential role for bacterial lipopeptides in enhanced binding of RSV and other viruses to their target cells, thus affecting viral entry or spread independent of TLR signaling. Moreover, our results also suggest a potential application for these synthetic lipopeptides as adjuvants for live-attenuated viral vaccines.
authors.affiliation: Department of Virology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
authors.forename: D Tien
authors.initials: DT
authors.lastname: Nguyen
authors.forename: Lot
authors.initials: L
authors.lastname: de Witte
authors.forename: Martin
authors.initials: M
authors.lastname: Ludlow
authors.forename: Selma
authors.initials: S
authors.lastname: Yüksel
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Wiesmüller
authors.forename: Teunis B H
authors.initials: TB
authors.lastname: Geijtenbeek
authors.forename: Albert D M E
authors.initials: AD
authors.lastname: Osterhaus
authors.forename: Rik L
authors.initials: RL
authors.lastname: de Swart
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D006801:Humans; D055666:Lipopeptides / Q000737:chemistry / Q000494:pharmacology*; D008459:Measles virus / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D029121:Metapneumovirus / Q000187:drug effects / Q000378:metabolism / Q000472:pathogenicity; D018357:Respiratory Syncytial Virus Infections / Q000378:metabolism* / Q000382:microbiology; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000378:metabolism* / Q000472:pathogenicity*; D051193:Toll-Like Receptors / Q000378:metabolism
chemical_list: D000276:Adjuvants, Immunologic; D055666:Lipopeptides; C508075:Pam(3)CSK(4) peptide; D051193:Toll-Like Receptors
references.citation: Emerg Infect Dis. 2004 Jul;10(7):1318-20
references.pmid: 15324559
references.citation: Cell. 2007 Dec 14;131(6):1059-71
references.pmid: 18083097
references.citation: Arch Virol. 1978;56(3):227-36
references.pmid: 565198
references.citation: J Immunol. 2007 Oct 1;179(7):4357-66
references.pmid: 17878330
references.citation: Pediatrics. 2008 Aug;122(2):229-37
references.pmid: 18676537
references.citation: J Virol. 2002 Jul;76(13):6743-9
references.pmid: 12050387
references.citation: J Virol. 1999 Aug;73(8):6370-9
references.pmid: 10400729
references.citation: Mol Immunol. 2009 Mar;46(6):1084-91
references.pmid: 19027958
references.citation: J Immunol. 1972 Dec;109(6):1296-9
references.pmid: 4343749
references.citation: J Clin Invest. 2004 May;113(10):1473-81
references.pmid: 15146245
references.citation: J Immunol Methods. 2009 Dec 31;351(1-2):13-23
references.pmid: 19804781
references.citation: Am J Hyg. 1957 Nov;66(3):281-90
references.pmid: 13478578
references.citation: Pediatr Res. 2005 Dec;58(6):1198-203
references.pmid: 16306193
references.citation: Cell Microbiol. 2009 Sep;11(9):1399-408
references.pmid: 19500108
references.citation: Infect Immun. 2009 Feb;77(2):714-24
references.pmid: 19015258
references.citation: Cell. 2007 Sep 21;130(6):1071-82
references.pmid: 17889651
references.citation: Immunobiology. 1989 Nov;180(1):93-100
references.pmid: 2625355
references.citation: Histochem Cell Biol. 2003 Feb;119(2):103-8
references.pmid: 12610729
references.citation: Am J Hyg. 1957 Nov;66(3):291-300
references.pmid: 13478579
references.citation: Epidemiol Infect. 2008 Nov;136(11):1448-54
references.pmid: 18211724
references.citation: Retrovirology. 2009 May 06;6:42
references.pmid: 19419540
references.citation: J Virol. 2000 Nov;74(22):10508-13
references.pmid: 11044095
references.citation: Biochem Biophys Res Commun. 2009 Oct 30;388(4):621-5
references.pmid: 19686699
references.citation: J Clin Invest. 2008 Oct;118(10):3440-52
references.pmid: 18776939
references.citation: Biophys J. 2004 Feb;86(2):1234-42
references.pmid: 14747357
references.citation: Eur J Immunol. 2005 Jan;35(1):282-9
references.pmid: 15580661
references.citation: Pediatr Res. 2004 Jun;55(6):972-8
references.pmid: 15103015
references.citation: J Virol. 2006 Feb;80(4):1629-36
references.pmid: 16439519
references.citation: Nat Med. 2004 Aug;10(8):811-3
references.pmid: 15247911
references.citation: J Gen Virol. 1991 Nov;72 ( Pt 11):2685-96
references.pmid: 1940866
references.citation: Vaccine. 2000 Dec 8;19 Suppl 1:S51-5
references.pmid: 11163463
references.citation: J Virol. 2004 Aug;78(15):7867-73
references.pmid: 15254159
references.citation: Pediatr Pathol. 1990;10(4):491-502
references.pmid: 1695371
references.citation: J Immunol. 1990 Mar 15;144(6):2394-9
references.pmid: 2107259
references.citation: Clin Exp Immunol. 2004 Jul;137(1):8-11
references.pmid: 15196237
references.citation: J Med Virol. 2004 Jun;73(2):300-8
references.pmid: 15122808
references.citation: Immunol Cell Biol. 2007 Aug-Sep;85(6):463-70
references.pmid: 17680012
references.citation: Curr Opin Immunol. 2003 Feb;15(1):5-11
references.pmid: 12495726
references.citation: J Virol. 2010 May;84(9):4714-24
references.pmid: 20181691
references.citation: FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):189-95
references.pmid: 10575129
references.citation: Virology. 2000 Jun 5;271(2):264-75
references.pmid: 10860881
references.citation: Methods Mol Biol. 2007;379:15-34
references.pmid: 17502668
references.citation: J Infect. 2009 Jan;58(1):37-46
references.pmid: 19042025
references.citation: Clin Infect Dis. 2000 May;30(5):784-9
references.pmid: 10816149
references.citation: J Biol Chem. 2007 Jul 20;282(29):21145-59
references.pmid: 17462991
references.citation: Arch Dis Child. 2004 Dec;89(12):1155-7
references.pmid: 15557055
references.citation: Virology. 2002 May 10;296(2):204-11
references.pmid: 12069519
references.citation: Curr Opin Struct Biol. 2007 Aug;17(4):427-36
references.pmid: 17870467
references.citation: J Immunol. 2005 Jun 15;174(12):7995-8002
references.pmid: 15944306
references.citation: Clin Exp Allergy. 2008 Nov;38(11):1819-29
references.pmid: 18644025
references.citation: Lancet. 1999 Sep 4;354(9181):847-52
references.pmid: 10485741
references.citation: J Infect Dis. 2005 Feb 1;191(3):382-6
references.pmid: 15633097
references.citation: Vaccine. 2008 Jul 4;26(29-30):3735-41
references.pmid: 18539368
references.citation: J Virol. 2009 Jan;83(1):73-80
references.pmid: 18945786
references.citation: J Immunol. 2008 Sep 15;181(6):3823-33
references.pmid: 18768836
references.citation: Pediatr Infect Dis J. 1987 Dec;6(12):1134-5
references.pmid: 3431985
references.citation: J Virol Methods. 2007 Aug;143(2):169-74
references.pmid: 17420056
references.citation: Blood. 2009 May 21;113(21):5157-66
references.pmid: 19279330